No patients in the placebo group had clinical remission at week 10 , compared with eight ( 21 % [ 95 % CI 7-36 ] ) patients in the etrolizumab 100 mg group ( p = 00040 ) and four ( 10 % [ 02-24 ] ) patients in the 300 mg plus LD group ( p = 0048 ) .